ADARA announces expansion into the Nordics and plans for further European growth
6.11.2019 11:00:00 EET | Business Wire | Press release
ADARA, the leader in predictive traveller intelligence, today announces its expansion into the Nordic market for the first time, with the appointment of Jonas Jonsborg as Regional Manager, Nordics ADARA. In addition to the hire, ADARA also announces new recent data partnerships with Momondo, HotelsCombined and Cheapflights, which will further bolster its presence in Europe and support brands in the region.
Comprising over 850 million monthly unique traveller profiles across more than 200 leading travel brands, ADARA’s travel data co-op offers a holistic view of traveller behaviour and preferences along the entire customer journey. Since expanding into the region in 2013, ADARA has established a strong presence in Europe with the appointment of Curtis Nishijima as Managing Director, EMEA in 2018 and with key hires in the UK, Germany, France and Spain. ADARA has also seen an increase in its EMEA data profiles of 38% year on year, furthering bolstering their data presence in the region.
Building on the success in these markets, ADARA is now strengthening its presence in the Nordics, one of the fastest-growing travel markets in EMEA. Tourism in the Nordics has seen a significant rise in recent years; since 2014 the region had an annual growth of 6% - 8.5% in the number of hotel nights. The expansion seeks to enable travel brands and agencies to tap into the increased demand by tourists to and from the Nordic region by offering holistic data insights that can be used to create personalised marketing campaigns based on the complete view of the traveller.
The depth and applicability of ADARA’s data go beyond the travel and tourism industries. Other sectors in the Nordics such as luxury retail, financial services and automotive can also take advantage of ADARA’s understanding of traveller purchase behaviour and ADARA can provide these brands with solutions that improve marketing performance and help achieve deeper personalisation using actionable data.
In his new role, Jonas will spearhead ADARA’s expansion into the Nordic markets, drawing on his extensive understanding and experience in data and advertising technology. Jonas has previously held executive positions at Adform, Microsoft, Meetrics and Audience Project.
Jonas Jonsborg, Regional Manager at ADARA Nordics said: “The Nordic market is experiencing a huge gap, one that can only be filled by ADARA. The breadth and depth of the data is unparalleled, and will be invaluable to Nordic partners. I look forward to leveraging my experience in the Nordics and strong belief in ADARA’s value proposition to grow the business and establish new data partners in the region.”
Curtis Nishijima, Managing Director, EMEA said “Jonas has an exceptional range of skills that make him the perfect person to spearhead our Nordic expansion. He has a strong knowledge of the region and a deep understanding of our industry.
-ENDS-
About Momondo
Momondo is a travel fare aggregator and travel fare metasearch engine headquartered in Copenhagen. Momondo also operates a travel information blog, Inspiration. The website is part of the Kayak.com subsidiary of Booking Holdings.
About Hotelscombined
HotelsCombined, a unit of Booking Holdings, is a hotel metasearch engine founded in 2005. The site operates in over 42 languages, handles 130 different currencies and aggregates more than 2 million deals from hundreds of travel sites and hotel chains.
About Cheapflights
Cheapflights is a travel fare aggregator and travel fare metasearch engine headquartered in London, UK. The website is part of the Kayak.com subsidiary of Booking Holdings. Its websites publish flight prices, and compare prices from suppliers, including major airlines, through tiny travel agents.
About ADARA
ADARA. Know What Travellers Need Next.
ADARA empowers the world's leading travel brands to grow the industry together. Built on the world's richest travel data co-op, ADARA offers people-based insights for travel companies. Clients get a value-based understanding of their relationship with their customers, with travel patterns, trends and behavior from more than 850 million monthly unique traveler profiles across more than 200 of the world's top travel brands. ADARA delivers critical intelligence to activate personalisation and relevance throughout the customer journey for sustainable growth. Its offerings span the three core pillars – Learn, Act, Measure & Modify – to drive measurable outcomes at the customer level. https://www.adara.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005106/en/
Contact information
For more information please contact:
Ben Tozer / Louise Watson
adara@propellergroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom